TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:27
Alphatec Holdings Inc. ( ATEC ) https://www.atecspine.com
9.33USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-39.26%
ATEC
SPY
32.66%
-21.73%
ATEC
SPY
108.59%
ATEC
31.59%
SPY
302.52%
-41.54%
ATEC
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1338.78
1792.52
1.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.53
2.85
-982.95
-23.91
0.00
-28.34
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-70.23
214.06
-16.64
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.76
-27.30
-28.37
1.75
Other Earnings and Cash Flow Stats:
Alphatec Holdings Inc. ( ATEC ) Net Income TTM ($MM) is -177.87
Alphatec Holdings Inc. ( ATEC ) Operating Income TTM ($MM) is -147.39
Alphatec Holdings Inc. ( ATEC ) Owners' Earnings Annual ($MM) is 0.00
Alphatec Holdings Inc. ( ATEC ) Current Price to Owners' Earnings ratio is 0.00
Alphatec Holdings Inc. ( ATEC ) EBITDA TTM ($MM) is -69.55
Alphatec Holdings Inc. ( ATEC ) EBITDA Margin is -16.64%
Capital Allocation:
Alphatec Holdings Inc. ( ATEC ) has paid 0.00 dividends per share and bought back -21.024 million shares in the past 12 months
Alphatec Holdings Inc. ( ATEC ) has reduced its debt by 8.341 million USD in the last 12 months
Capital Structure:
Alphatec Holdings Inc. ( ATEC ) Interest-bearing Debt ($MM) as of last quarter is 534
Alphatec Holdings Inc. ( ATEC ) Annual Working Capital Investments ($MM) are 17
Alphatec Holdings Inc. ( ATEC ) Book Value ($MM) as of last quarter is -2
Alphatec Holdings Inc. ( ATEC ) Debt/Capital as of last quarter is -39260%
Other Balance Sheet Stats:
Alphatec Holdings Inc. ( ATEC ) has 80 million in cash on hand as of last quarter
Alphatec Holdings Inc. ( ATEC ) has 156 million of liabilities due within 12 months, and long term debt 527 as of last quarter
Alphatec Holdings Inc. ( ATEC ) has 143 common shares outstanding as of last quarter
Alphatec Holdings Inc. ( ATEC ) has 0 million USD of preferred stock value
Academic Scores:
Alphatec Holdings Inc. ( ATEC ) Altman Z-Score is -1.07 as of last quarter
Alphatec Holdings Inc. ( ATEC ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Alphatec Holdings Inc. ( ATEC ) largest shareholder is owning shares at 0.00 ($MM) value
Sponsel David(an insider) Sold 62018 shares of Alphatec Holdings Inc. ( ATEC ) for the amount of $600954.42 on 2024-12-11
26.68% of Alphatec Holdings Inc. ( ATEC ) is held by insiders, and 65.60% is held by institutions
Alphatec Holdings Inc. ( ATEC ) went public on 2006-06-02
Other Alphatec Holdings Inc. ( ATEC ) financial metrics:
FCF:-187.33
Unlevered Free Cash Flow:0.00
EPS:-1.10
Operating Margin:-70.23
Gross Profit Margin:214.06
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:11634.65
Beta:1.75
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Alphatec Holdings Inc. ( ATEC ) :
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. It manufactures and sells implants and instruments through third-party suppliers. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform; Sigma PTP Access and Patient Positioning System; split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; EOS imaging system that provides full-body imaging; spinal implants and fixation systems; and NanoTec and Calibrate PSX, as well as various standalone implants for height restoration and stabilization. It also provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix, a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM; AlphaGRAFT Demineralized Bone Matrix comprising demineralized human tissues; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives in the United States and internationally. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.